Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255716 | 0.98 | SMN1; SMN2 (0.60) | SMN1; SMN2TSHREPHX2GABRA5GABRB2 | |
| Methoxymethane SCHEMBL18550632 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2TSHREPHX2GABRA5GABRB2 | |
| SCHEMBL5026008 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2TSHREPHX2HSD17B10CSNK2A1 | |
| SCHEMBL18116435 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2TSHREPHX2HSD17B10CSNK2A1 | |
| SCHEMBL5835647 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2TSHREPHX2HSD17B10CSNK2A1 | |
| Bromide SCHEMBL1636830 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2TSHREPHX2HSD17B10ALDH1A1 | |
| SCHEMBL13851673 | 0.77 | HRH2 (0.52) | SMN1; SMN2TSHREPHX2CSNK2A1ALDH1A1 | |
| SCHEMBL18116109 | 0.77 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHREPHX2HSD17B10CSNK2A1 | |
| SCHEMBL1636834 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHREPHX2HSD17B10ALDH1A1 | |
| SCHEMBL28861538 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1MAPTL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | SMN1; SMN2 1989/4885TSHR 2810/4885EPHX2 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.